# PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma

> **NCT04305405** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 30 (actual)

## Conditions studied

- Severe Uncontrolled Asthma

## Interventions

- **DRUG:** Benralizumab

## Key facts

- **NCT ID:** NCT04305405
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-21
- **Primary completion:** 2022-09-12
- **Final completion:** 2022-09-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-05-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305405, "PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04305405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*